Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Arizona: - Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Arizona: - University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Arizona: - Mayo Clinic - Arizona — Phoenix, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Arizona: - Mayo Clinic Arizona — Phoenix, Arizona
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Arizona: - HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Arizona: - Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Arizona: - Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Arizona: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Arizona: - Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Arizona: - Mayo Clinic_Arizona — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Arizona: - Mayo Clinic Scottsdale — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Academic/Other
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…
Sponsor: University of Arizona
NCT ID: NCT06814496
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…
Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Arizona: - Mayo Clinic Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a pe…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06160206
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1 Recruiting Industry
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The …
Sponsor: Tcelltech Inc.
NCT ID: NCT06482905
Sites in Arizona: - Mayo Clinic in Arizona — Phoenix, Arizona
Phase 1 Recruiting Academic/Other
This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely giv…
Sponsor: Mayo Clinic
NCT ID: NCT05030298
Sites in Arizona: - Mayo Clinic in Arizona — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. …
Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
NCT ID: NCT06072586
Sites in Arizona: - Chandler Regional Medical Center — Chandler, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 12 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are sc…
Sponsor: Nader Sanai
NCT ID: NCT06883747
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main question…
Sponsor: University of Arizona
NCT ID: NCT06055790
Sites in Arizona: - Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, multi-center, Phase 0/2 trial designed to enroll up to 78 total participants with suspected newly diagnosed glioblastoma (nGBM) who are scheduled for surgical resection to accrue at least 14 participants in Arm A and…
Sponsor: Nader Sanai
NCT ID: NCT07485049
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Arizona: - HonorHeath Scottsdale Osborn Medical Center — Phoenix, Arizona
NA Recruiting Industry
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
Sponsor: Alpha Tau Medical LTD.
NCT ID: NCT06910306
Sites in Arizona: - Honor Health — Scottsdale, Arizona
NA Recruiting Academic/Other
This is a prospective, single-blinded, multicenter study evaluating the benefit of sinonasal irrigations following endoscopic pituitary surgery. The goal of this study is to create practice changing guidelines with objective data highlight…
Sponsor: Lori Wood
NCT ID: NCT05659524
Sites in Arizona: - Barrow Neurological Institute at St. Joseph's Hospital and Medical Center — Phoenix, Arizona